Stay updated on Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page
- ChecktodayChange DetectedAdded downloadable documents for the study (Statistical Analysis Plan and Study Protocol) along with metadata, and updated record dates and related keywords to reflect current documentation for the trial.SummaryDifference100%

- Check7 days agoChange DetectedThe page now displays a 403 Forbidden message with a simple header and a Home link, and previously available study content and documents are removed; navigation remains possible but the study information is no longer accessible.SummaryDifference18%

- Check14 days agoChange DetectedThe page metadata now shows Revision: v3.7.0, replacing the previous Revision: v3.6.6. This indicates a non-content update to the site/template rather than changes to the study data.SummaryDifference0.0%

- Check35 days agoChange DetectedA funding source entry for NIH grant/contract was added to the study record. This reflects NIH support for the trial.SummaryDifference0.0%

- Check56 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing the previous Revision: v3.6.4. This is a metadata-level update to the page template and does not alter study content or functionality.SummaryDifference0.0%

- Check63 days agoChange DetectedA new citation for Lenvatinib plus pembrolizumab outcomes (KEYNOTE-775/LEAP-001) has been added to the Publications section, listing the authors and journal details. The previous 'Online ahead of print' note has been removed.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Combo With Pembrolizumab in Endometrial Cancer Clinical Trial page.